Tag: revance therapeutics

All

Revance Reports Q4 and Full Year 2021 Financial Results; Credits Dermal Filler Sales for Growth

The company also announced progress on its DaxibotulinumtoxinA for Injection for glabellar lines and intent to launch the RHA Redensity dermal filler in the second half of 2022.

Revance Resubmits BLA to FDA for DaxibotulinumtoxinA for Injection
Revance Closes on $300M Note Purchase Agreement with Athyrium Capital Management
FDA Accepts Revance Resubmission for Frown Line Treatment
FDA Approves Revance Daxxify for Frown Lines
Studies Show Efficacy of Daxxify to Treat Frown Lines
Revance Publishes 2 Papers on Daxxify Injectable

All

Sorry, No Posts Found

All

APX Lays Out Workshops for Florida Plastic Surgery Forum

APX Platform announced four educational workshops during the staff program breakout session at the 2022 Florida Plastic Surgery Forum.

Going Green in Operating Rooms Reduces Cost and Improves Environmental Impact
New AI Tools Help Med Spa Patients Visualize the End Results
Study Shows Social Media is Shaping Gen Z Values